IMMUNOPRECISE ANTIBODIES LTD. (TSX-V: IPA) (OTC PINK: IPATF) announces that it has closed its previously announced non-brokered private placement financing by issuing a total of 9,102,500 units of ImmunoPrecise at a price of $1.00 per Unit for gross proceeds of $9,102,500.  Due to strong investor demand, the Financing was oversubscribed by $2,102,500.

Each Unit sold in the Financing consists of one common share of ImmunoPrecise and one share purchase warrant of ImmuoPrecise, with each Warrant entitling the holder to purchase an additional Share at a price of $1.25 for a period of two years from the date of issue.  ImmunoPrecise will have the right to accelerate the expiry date of the warrants provided that ImmunoPrecise’s volume weighted average price trades at a price equal to or greater than $1.75 for a period of 20 consecutive days.  In the event of acceleration, the expiry date will be accelerated to a date that is 30 days after ImmunoPrecise issues a news release announcing that it has elected to exercise this acceleration right.

The securities issued under the Financing will be subject to restrictions on resale until January 25, 2019.  Under the Financing, ImmunoPrecise paid finders cash fees totaling $173,940 and 182,460 Shares.

The proceeds of the Financing will be used to expand operations and sales in the United States, Canada and Europe.

Debenture Settlement

ImmunoPrecise also wishes to announce that it wishes to settle up to $1,377,000 of previously issued debentures by issuing up to 1,377,000 Units at a price of $1.00 per Unit.  Each Unit is on the same terms as the Financing. The purpose of the Debt Settlement is to reduce the ongoing debt obligations of the Debentures. The Debt Settlement is subject to the approval of the TSX Venture Exchange.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, which house its tissue culture and B-cell screening facilities, as well as a Canadian Council for Animal Care (CCAC)-approved animal care unit. ImmunoPrecise operates globally to offer antibody services from target analysis to pre-clinical lead generation, in collaboration with its subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands.

The services offered to clients include antibody discovery in wild-type and humanized mouse and rat models, as well as rabbit monoclonal antibodies, all against a broad spectrum of antigens. The Company also offers a wide range of species agnostic B-cell screening and sorting services that decrease discovery timelines and enhance the probability of finding a therapeutic antibody of interest. In addition, the Company provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, phage display, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development.  In addition, cryopreservation services are provided for the storage of valuable biological materials including hybridoma clones, plasmid constructs, and cell lines. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.

ImmunoPrecise employs a highly experienced group of R&D scientists. Over the last 25 years, investments in innovative and proprietary technologies and methods have vastly improved the speed and efficiency of monoclonal and polyclonal antibody production.